Can one stop nucleic acid sampling (OSNA) predict nodal positivity following neoadjuvant chemotherapy? A prospective cohort study of 293 patients.
Until recently, axillary node clearance had long been the standard of care in patients with axillary node‐positive disease. One stop nucleic acid sampling (OSNA) has been used to guide intraoperative decision‐making regarding suitability for axillary node clearance (ANC). The aim of this study is to...
| Publicado en: | Breast Journal Vol. 27; no. 7; pp. 581 - 586 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jul2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151398559&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 151398559 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1075122X ET6 jtl: Breast Journal issn: 1075122X maglogo: Y pubinfo: dt: Jul2021 vid: 27 iid: 7 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 151398559 149832774 151398559 151398559 10.1111/tbj.14233 151398559 ppf: 581 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Can one stop nucleic acid sampling (OSNA) predict nodal positivity following neoadjuvant chemotherapy? A prospective cohort study of 293 patients. aug: au: Batt, Jeremy Schrire, Timothy Rayter, Zenon affil: Bristol Breast Care Centre, North Bristol NHS Trust, Southmead Hospital, Bristol, UK sug: subj: Neoadjuvant Therapy Chemotherapy, Cancer Breast Neoplasms Drug Therapy Nucleic Acids Lymphoma Human Cancer Patients Prospective Studies Disease Progression ab: Until recently, axillary node clearance had long been the standard of care in patients with axillary node‐positive disease. One stop nucleic acid sampling (OSNA) has been used to guide intraoperative decision‐making regarding suitability for axillary node clearance (ANC). The aim of this study is to evaluate the use of OSNA following neoadjuvant chemotherapy (NACT) and whether it can predict lymph node burden in ANC. A single center, prospective cohort study was performed on 297 patients having OSNA between 2016 and 2019. Patients were sub‐classified according to node positivity at diagnosis and those treated with NACT and outcomes included copy number and lymph node harvest. Axillary complete pathological response was observed in 24/36 patients (67%) following NACT. 14/16 patients (87%) having axillary node clearance had axillary node disease limited to 4 nodes. OSNA copy numbers were significantly higher in patients showing disease progression following NACT. Overall, 73% of patients with lymph node positivity at diagnosis could be successfully treated with a combination of NACT and lymph node excision of four nodes. De‐escalating axillary surgical treatment to resection of four nodes following NACT may be effective in balancing oncological resection and limiting treatment morbidity. ONSA can correctly identify patients experiencing disease progression who would benefit from traditional three‐level ANC. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|